Open AccessCurrent and Emerging Therapeutic Options for Hairy Cell Leukemia Variant
Author(s) -
Qiuying Liu,
Nicholas Harris,
Narendranath Epperla,
Leslie A. Andritsos
Publication year - 2021
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s242247
Subject(s) - hairy cell leukemia , chemoimmunotherapy , medicine , leukemia , clinical trial , cladribine , cancer research , therapeutic effect , therapeutic approach , oncology , disease , chronic lymphocytic leukemia , immunology
Hairy cell leukemia variant (HCL-v) is a rare B-cell lymphoproliferative disorder with distinct immunophenotypic and molecular characteristics when compared to classical hairy cell leukemia (HCL-c). In contrast to the enormous progress in therapeutic options for HCL-c, HCL-v remains a therapeutic challenge due to inferior outcomes with standard chemoimmunotherapy and BCR signaling pathway inhibitors, and due to the fact that HCL-v has limited molecular therapeutic targets. In addition, because of the rarity of the disease, there is a paucity of later phase studies or multicenter trials to guide treatment decisions. In this article, we briefly review the diagnostic criteria and clinical characteristics of HCL-v and present a comprehensive overview of current therapeutic options in HCL-v.